A Randomised Phase II study comparing the efficacy of 5azacitidine alone versus combination therapy with lenalidomide and 5azacitidine in patients with higher risk myelodysplastic syndromes (MDS) and low marrow blast count acute myeloid leukaemia (AML).

DOI number 10.58109/e8xk-3g33
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Melita Kenealy (Peter MacCallum Cancer Centre)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 160 patients with newly diagnosed MDS
  • Patients were randomised to receive lenalidomide and 5azacitidine or 5azacitidine alone
  • Demographic data
  • Diagnostic data
  • Treatment data
  • Outcome data
  • Measures of supportive care during treatment, Eg transfusion requirements, QoL
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Chemotherapy
ANZCTR Reference ACTRN12610000271000
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
MDS03
MM06